In Vitro Efficacy of Moxidectin versus Ivermectin against Sarcoptes scabiei-Reference-Cited by-同舟云学术

In Vitro Efficacy of Moxidectin versus Ivermectin against Sarcoptes scabiei

Published:2017-08 Issue:8 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Mounsey Kate E.¹^ORCID,Walton Shelley F.¹,Innes Ashlee¹,Cash-Deans Skye¹,McCarthy James S.²³

Affiliation:

1. Inflammation and Healing Cluster, School of Health & Sport Sciences, Faculty of Science, Health, Education, and Engineering, University of the Sunshine Coast, Sippy Downs, Australia

2. QIMR Berghofer Medical Research Institute, Herston, QLD, Australia

3. University of Queensland, Herston, QLD, Australia

Abstract

ABSTRACT Moxidectin is under consideration for development as a treatment for human scabies. As some arthropods show decreased sensitivity to moxidectin relative to ivermectin, it was important to assess this for Sarcoptes scabiei . In vitro assays showed that the concentration of moxidectin required to kill 50% of mites was lower than that of ivermectin (0.5 μM versus 1.8 μM at 24 h; P < 0.0001). This finding provides further support for moxidectin as a candidate for the treatment of human scabies.

Funder

University of the Sunshine Coast

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00381-17

Reference36 articles.

1. Prospects for Moxidectin as a New Oral Treatment for Human Scabies

2. The Antiparasitic Moxidectin: Safety, Tolerability, and Pharmacokinetics in Humans

3. The pharmacokinetics and metabolism of ivermectin in domestic animal species